reports
- Jacob Mekhael
Galapagos GLPG3667 phase 2 hits topline in DM, but misses in SLE
Galapagos announced the topline results from 2 phase 2 studies evaluating the efficacy and safety of GLPG3667 (TYK2 inhibitor) in dermatomyositis (DM, GALARISSO study) and active systemic lupus erythematosus (SLE, GALACELA study). The GALARISSO study in DM met its primary endpoint showing a 14.26 delta on the TIS measure at 24 weeks, which compares favourably to brepocitinib (TYK2/JAK1 inhibitor) in our view. In the GALACELA study in SLE patients, primary endpoint at 32 weeks was not met, but fi...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Michiel Declercq
- Thibault Leneeuw
- Wim Lewi
Galapagos Announces Topline Results from Two Phase 3-Enabling Studies ...
Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor GLPG3667 in Dermatomyositis and Systemic Lupus Erythematosus GLPG3667 met primary endpoint in dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on secondary measures of disease activity compared to placebo In the systemic lupus erythematosus study, GLPG3667 delivered numerical improvements on several secondary endpoints compared to placebo but did not achieve statistical significance in primary endpoint analysis The safety profile ...
Galapagos maakt topline resultaten bekend van twee fase 3-enabling stu...
Galapagos maakt topline resultaten bekend van twee fase 3-enabling studies met selectieve TYK2-remmer GLPG3667 bij dermatomyositis en systemische lupus erythematodes GLPG3667 bereikte het primaire eindpunt in de dermatomyositis-studie en toonde een statistisch significant klinisch voordeel en betekenisvolle verbeteringen aan op secundaire eindpunten van ziekteactiviteit in vergelijking met placebo In de studie naar systemische lupus erythematodes leverde GLPG3667 numerieke verbeteringen op voor verschillende secundaire eindpunten in vergelijking met placebo, maar bereikte het geen statisti...
- ING Helpdesk
Arcadis reports transactions under its current share buyback program
Arcadis reports transactions under its current share buyback program PRESS RELEASEArcadis reports transactions under its current share buyback program Amsterdam, 16 December 2025 – Arcadis N.V. (Arcadis), the world’s leading company delivering data-driven sustainable design, engineering, and consultancy solutions for natural and built assets, repurchased 327,154 of its own shares in the period 8 – 12 December 2025 at an average price of €36.24. The total consideration of this repurchase was €11,855,299. The total number of shares repurchased under this program to date is 2,798,182 shares...
- Marc Hesselink
- CFA
- Thymen Rundberg
Adyen/Built for growth/BUY
We remain positive on the Adyen investment case. Its recent CMD underpinned solid growth guidance for the years ahead, and we believe the company's strong foundation, its in-house built end-to-end payment platform, positions it well for further market share gains and long-term growth drivers like agentic commerce. We keep our target price of €1,850 unchanged and reiterate our BUY rating.
- Delphine Brault
- Nathan Mietlicki
- Delphine Brault
- Nathan Mietlicki
- ING Helpdesk
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Mathijs Geerts Danau
- Michiel Declercq
- Thibault Leneeuw
- Wim Lewi
- Kristof Samoy
Arcadis 26 year company veteran and GBA-head of Resilience to become n...
Arcadis has nominated Heather Polinsky as its next CEO, effective 1 March 2026, pending shareholder approval at the Annual General Meeting next May. Alan Brookes will step down earlier than expected, as his term was originally set to run until 2027. The leadership change is intended to reinvigorate growth and strengthen the company's market position ahead of its next strategic cycle. Arcadis has missed its organic growth targets from the 2023 CMD, with year-to-date topline growth in 2025 at only...
- Martijn Den Drijver
Arcadis announces Heather Polinsky as new CEO
Arcadis announces Heather Polinsky as new CEO PRESS RELEASE Arcadis announces Heather Polinsky as new CEO Heather Polinsky, 26-year veteran of the company and Global President for Resilience and Mobility, nominated as new Chief Executive Officer (CEO)Alan Brookes to step down as CEO on 1 March 2026 Amsterdam, 11 December 2025 – Arcadis (EURONEXT: ARCAD), the world’s leading company in delivering data-driven sustainable design, engineering, and consultancy solutions for natural and built assets, today announced that the Supervisory Board has nominated Heather Polin...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Mathijs Geerts Danau
- Michiel Declercq
- Wim Hoste
- Wim Lewi
Arcadis reports transactions under its current share buyback program
Arcadis reports transactions under its current share buyback program PRESS RELEASEArcadis reports transactions under its current share buyback program Amsterdam, 9 December 2025 – Arcadis N.V. (Arcadis), the world’s leading company delivering data-driven sustainable design, engineering, and consultancy solutions for natural and built assets, repurchased 460,622 of its own shares in the period 1 – 5 December 2025 at an average price of €37.42. The total consideration of this repurchase was €17,237,189. The total number of shares repurchased under this program to date is 2,471,028 shares f...
- Hilde Van Boxstael
- Mathijs Geerts Danau
- Michiel Declercq
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 202...
Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025 High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time Mechelen, Belgium; December 8, 2025, 07:30 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announced new and updated Phase 2 data from the ongoing ATALANTA-1 study with its CD19 CAR T-cell therapy candidate, GLPG5101, during an oral presentation (#662) at the 67th American Society of Hematol...
Galapagos presenteerde nieuwe ATALANTA-1 celtherapiedata in MCL op ASH...
Galapagos presenteerde nieuwe ATALANTA-1 celtherapiedata in MCL op ASH 2025 Hoge percentages complete respons en minimale residuele ziekte (MRD)-negativiteit, met duurzame responsen, bij hoog-risico mantelcellymfoom (MCL) met GLPG5101, een verse, early-memory verrijkte CAR T-celtherapie met een vein-to-vein-tijd van 7 dagen Mechelen, België; 8 december 2025, 07:30 CET; Galapagos NV (Euronext & NASDAQ: GLPG) kondigde nieuwe en geüpdatete fase 2-gegevens aan uit de lopende ATALANTA-1-studie met haar CD19 CAR T-celtherapiekandidaat GLPG5101, tijdens een mondelinge presentatie (#662) op de 67s...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.